NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

Now Viewing

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

Video content above is prompted by the following question(s):

• Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?

Related Videos

Related Content

Advertisement

April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

Related Content

Advertisement

April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.